Xconomy -- Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ:ALNY) has found another partner to help it deliver its gene-silencing drugs to tissues deep in the body. Precision NanoSystems, of Vancouver, British Columbia, has agreed to lend Alnylam its expertise in using its so-called small lipid nanoparticles to potentially deliver RNA-interference (RNAi) drugs, the companies said today. The tiny particles could help advance Alnylam’s gene-silencing drugs through the liver, which has proved a difficult barrier to homing in on tissues deeper in the body with such treatments.
